Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Patients with untreated extensive-stage small cell lung cancer(SCLC) were randomly assigned
to receive either irinotecan/cisplatin (IP) or etoposide/cisplatin(EP), The association of
efficacy and toxicity of IP regimen was analyzed.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
China-Japan Friendship Hospital Chinese PLA General Hospital